| Biomarker ID | 1433 |
| PMID | 24893170 |
| Year | 2014 |
| Biomarker | miR-19a |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Cases |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 9.22 (95% CI: 2.27 - 37.43) p=0.002 |
| Effect on Pathways | Pathways include: DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; chromatin; regulation of RNA metabolic process; nuclear chromosome |
| Experiment | Gleason Score ≥7 or Gleason Score =6 |
| Type of Biomarker | Prognostic |
| Cohort | A validation cohort consisted of 25 cases and 35 controls. Gleason score of 7 or higher (case group) and a pathologic Gleason score of 6 (control group). |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.85 (95% CI: 0.75- 0.95) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |